Return to homepagePandemic Pact

BRTX - Repositioning of Breathox® to COVID-19 indication

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Innovationsfonden Denmark

  • Research Location

    Denmark

  • Lead Research Institution

    Liita Care ApS, AAUH, SSI, Trial Nation

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The purpose of this project is to reposition Breathox® salt particle inhaler - which is designed to clean the airways and relieve respiratory irritation by e.g. colds, hay fever, asthma and COPD - as a complementary treatment option for COVID-19 patients. The project will i.a. verify the basic assumptions that COVID-19 RNA is affected by antiviral immune response caused by increase in salt concentration, as seen with other DNA and RNA viruses, and that Breathox® has a virus-inhibiting effect on COVID-19 patients.